Beth Marsh is stepping into the role of Neurotech Pharmaceuticals’ chief commercial officer (CCO) beginning April 28. Marsh will lead the organization, particularly as it prepares for the US launch of ...

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications. The US Food and Drug ...

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies ...